ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -2 مورد

Unfavorable prognosis early-stage classic Hodgkin lymphoma: Response-guided therapy

Unfavorable prognosis early-stage classic Hodgkin lymphoma: Response-guided therapy
This algorithm describes response-guided management of unfavorable prognosis early-stage cHL. Refer to related UpToDate material for details of diagnosis, staging, prognostic category, PET scoring, chemotherapy regimens, and monitoring. Where treatment options are listed, either approach is acceptable.

ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; AVD: doxorubicin, vinblastine, and dacarbazine; cHL: classic Hodgkin lymphoma; ESR: erythrocyte sedimentation rate; Gy: gray; PET: positron emission tomography; RT: radiation therapy.

* Choice of approach is guided by individual risk factors and comorbidities; refer tp related UpToDate material for examples.

¶ Some experts instead favor treatment with intensified chemotherapy, as discussed in related UpToDate material.

Δ Biopsy to exclude other diagnoses (eg, infection, gray zone lymphoma, other cancers). If there is no viable cHL, treat like partial response. Persistent cHL is treated like refractory cHL, as discussed in related UpToDate material.

◊ Research groups apply different criteria for unfavorable prognosis; refer to related UpToDate material for details of prognostic scoring criteria.
Graphic 145182 Version 1.0